Results 91 to 100 of about 28,519 (248)

Modulation of C5a–C5aR1 signaling alters the dynamics of AD progression

open access: yesJournal of Neuroinflammation, 2022
Background The complement system is part of the innate immune system that clears pathogens and cellular debris. In the healthy brain, complement influences neurodevelopment and neurogenesis, synaptic pruning, clearance of neuronal blebs, recruitment of ...
Klebea Carvalho   +10 more
doaj   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler   +4 more
wiley   +1 more source

NOD2-mediated suppression of CD55 on neutrophils enhances C5a generation during polymicrobial sepsis. [PDF]

open access: yesPLoS Pathogens, 2013
Nucleotide-binding oligomerization domain (NOD) 2 is a cytosolic protein that plays a defensive role in bacterial infection by sensing peptidoglycans. C5a, which has harmful effects in sepsis, interacts with innate proteins.
Sae Jin Oh, Ji Hyung Kim, Doo Hyun Chung
doaj   +1 more source

Contractile actions of C5a on isolated porcine myocardium [PDF]

open access: yes, 1992
Although intracoronary administration of the complement component, C5a, produces deleterious effects on regional coronary blood flow and segmental ventricular function, it is unclear whether a direct myocardial action contributes to the dysfunction ...
J. C. Longhurst   +2 more
core   +1 more source

Dilithium Enediamide Derived From 1,4‐Diaza‐1,3‐Diene: An Electron Reservoir Enabling Variable Reactivity Toward Carbonyl Compounds

open access: yesEuropean Journal of Inorganic Chemistry, EarlyView.
Upon reduction of 1,4‐diaza‐1,3‐diene 1 to the dilithium enediamide 2, the polarity of the C = N bonds is reversed ‐ a classic case of umpolung. This behavior is particularly evident in reactions of the dianion 2 with carbonyl compounds and also explains why 1,4‐diaza‐1,3‐diene ligands do not always act merely as spectator ligands. 1,4‐Diaza‐1,3‐dienes
Muhan Liang   +3 more
wiley   +1 more source

Development of C5a receptor antagonists [PDF]

open access: yes, 1999
During host defense, the human complement system of plasma proteins initiates inflammatory and cellular immune responses to stimuli such as infectious organisms, chemical and physical injury, radiation and neoplasia.
Taylor, S. M., Fairlie, D., Wong, A.
core  

Receptor activation by human C5a des Arg74 but not intact C5a is dependent on an interaction between Glu199 of the receptor and Lys68 of the ligand [PDF]

open access: yes, 1999
Despite the expression of only one type of receptor, there is great variation in the ability of different cell types to discriminate between C5a and its more stable metabolite, C5a des Arg74. The mechanism that underlies this phenomenon is not understood
Monk, Peter N.   +4 more
core   +1 more source

Regulatory effects of C5a on IL-17A, IL-17F, and IL-23

open access: yesFrontiers in Immunology, 2013
The complement anaphylatoxin, C5a, through binding to its receptors (C5aR or C5L2), has important biological properties for recruitment and activation of phagocytes.
Jamison J. Grailer   +2 more
doaj   +1 more source

Complement C5a Induces Pro-inflammatory Microvesicle Shedding in Severely Injured Patients

open access: yesFrontiers in Immunology, 2020
Initially underestimated as platelet dust, extracellular vesicles are continuously gaining interest in the field of inflammation. Various studies addressing inflammatory diseases have shown that microvesicles (MVs) originating from different cell types ...
Ebru Karasu   +10 more
doaj   +1 more source

Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patients

open access: yesIntensive Care Medicine Experimental, 2023
Background Vilobelimab, a complement 5a (C5a)-specific monoclonal antibody, reduced mortality in critically ill COVID-19 patients in a phase 3 multicentre, randomized, double-blind, placebo-controlled study.
Endry H. T. Lim   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy